A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Clinical Trials Bite Off Chunk of CAR T Therapy Market
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful.
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena | Nov 13, 2017
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro.
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.
Another CAR-T IPO
Jef Akst | Apr 6, 2015
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.
To Each His Own
Mary Beth Aberlin | Apr 1, 2015
Cancer treatment becomes more and more personal.